البلد: كندا
اللغة: الإنجليزية
المصدر: Health Canada
IBUPROFEN; METHOCARBAMOL
INTERNATIONAL PHARMACEUTICAL GENERICS LTD
M03BA53
METHOCARBAMOL, COMBINATIONS EXCL PSYCHOLEPTICS
200MG; 500MG
TABLET
IBUPROFEN 200MG; METHOCARBAMOL 500MG
ORAL
100
OTC
CENTRALLY ACTING SKELETAL MUSCLE RELAXANTS
Active ingredient group (AIG) number: 0248961001; AHFS:
CANCELLED PRE MARKET
2017-06-13
1 | P a g e PRODUCT MONOGRAPH MUSCLE RELAXANT & ANALGESIC CAPLETS 500 MG METHOCARBAMOL AND 200 MG IBUPROFEN TABLETS THERAPEUTIC CLASSIFICATION MUSCLE RELAXANT / ANALGESIC INTERNATIONAL PHARMACEUTICAL GENERICS LTD., Date of Preparation: 30 Malta Avenue, Suite 2408 February 01, 2010 Brampton, ON L6Y 4S5 Control#: 135919 2 | P a g e TABLE OF CONTENTS Clinical Pharmacology..............................................................................................................................3 Indications:................................................................................................................................................7 Contraindications ......................................................................................................................................8 Warnings:..................................................................................................................................................8 Precautions..............................................................................................................................................12 Drug Interactions ....................................................................................................................................13 Adverse Reactions ..................................................................................................................................15 Symptoms and Treatment of Overdose...................................................................................................17 Dosage and Administration.....................................................................................................................18 Pharmaceutical Information....................................................................................................................19 Composition:...........................................................................................................................................21 Availability of Dosage Forms............ اقرأ الوثيقة كاملة